Melphalan

製品コードS8266 バッチS826603

印刷

化学情報

Chemical Structure Synonyms Alkeran, Sarcolysin, L-PAM Storage
(From the date of receipt)		 3 years -20°C powder
1 years -80°C in solvent
化学式

C13H18Cl2N2O2
分子量 305.20 CAS No. 148-82-3
Solubility (25°C)* 体外 DMSO 3.5 mg/mL (11.46 mM)
Water Insoluble
Ethanol Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明 Melphalan (Alkeran, Sarcolysin, L-PAM) is a phenylalanine derivative of nitrogen mustard with antineoplastic activity.This product is a hazardous chemical (acute toxicity/flammable/skin corrosive). Please use it while wearing a protective face mask, gloves, and clothing.
in vitro Exposure of a myeloma cell line (RPMI 8226) to a 30-minute pulse of melphalan (1-phenylalanine-mustard) results in a cell cycle progression delay characteristic for DNA cross-linking agents[1]. Melphalan has been shown to bind to DNA, RNA, and protein in cells in vitro. Melphalan induces chromosomal aberrations, sister chromatid exchange, micronuclei, mutations at the HPRT gene, and DNA damage in human cells in vitro. It also induces transformation of C3H 10T1/2 and other cells. In cultured rodent cells, it induces chromosomal aberrations, sister chromatid exchange, gene mutations, and DNA damage. In addition, it induces aneuploidy and sex-linked recessive lethal mutations in Drosophila, and mutation in bacteria[3].
in vivo Melphalan has been tested in mice by oral, intraperitoneal, and dermal application; in rats by intraperitoneal injection, and in monkeys by oral administration. In mice, the administration of melphalan produced forestomach papillomas, lymphosarcomas, and skin and lung tumours. In rats, melphalan caused mammary gland tumours, and peritoneal sarcomas. Results in monkeys were inconclusive[3].

プロトコル(参考用のみ)

細胞アッセイ 細胞株 human myeloma cell line RPMI 8226
濃度
反応時間 30 min
実験の流れ Cells are cultured in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS), 1 % L-glutamine, 50 μg/ml of penicillin and 50 μg/ml of streptomycin. Cell viability is assessed by trypan blue exclusion. For the melphalan exposure, cells are collected from exponentially growing cell cultures. The cells were treated by a 30-min melphalan pulse in serum-free medium after which they are run in complete culture medium as described above without drug for various times.
動物実験 動物モデル Tg.AC mice
投薬量 0.25, 1, and 4 mg/kg weekly
投与方法 Topical administration/oral gavage

カスタマーフィードバック

Data from [Data independently produced by , , Blood, 2016, 127(9):1138-50. ]

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Dihydrolipoamide dehydrogenase (DLD) is a novel molecular target of bortezomib [ Cell Death Dis, 2024, 15(8):588] PubMed: 39138149
DNp73 enhances tumor progression and immune evasion in multiple myeloma by targeting the MYC and MYCN pathways [ Front Immunol, 2024, 15:1470328] PubMed: 39380995
Therapeutic potential of anti-PIK3CG treatment for multiple myeloma via inhibiting c-Myc pathway [ Heliyon, 2024, 10(1):e23165] PubMed: 38163179
Identification and targeting of protein tyrosine kinase 7 (PTK7) as an immunotherapy candidate for neuroblastoma [ Cell Rep Med, 2023, 4(6):101091] PubMed: 37343516
Identification and targeting of protein tyrosine kinase 7 (PTK7) as an immunotherapy candidate for neuroblastoma [ Cell Rep Med, 2023, 4(6):101091] PubMed: 37343516
Deneddylation of ribosomal proteins promotes synergy between MLN4924 and chemotherapy to elicit complete therapeutic responses [ Cell Rep, 2023, 42(8):112925] PubMed: 37552601
Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma [ Nat Commun, 2022, 13(1):1009] PubMed: 35197447
NEDD4L binds the proteasome and promotes autophagy and bortezomib sensitivity in multiple myeloma [ Cell Death Dis, 2022, 13(3):197] PubMed: 35236820
ISG20L2 suppresses bortezomib antimyeloma activity by attenuating bortezomib binding to PSMB5 [ JCI Insight, 2022, 7(19)e157081] PubMed: 36040812
Inhibition of the Protein Arginine Methyltransferase PRMT5 in High-Risk Multiple Myeloma as a Novel Treatment Approach [ Front Cell Dev Biol, 2022, 10:879057] PubMed: 35757005

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。